Table 4.
CDHR-NUS | SGD + MGD (136 patients) | SGD (126 patients) | MGD (10 patients) | EPP (25 patients) | ||||
---|---|---|---|---|---|---|---|---|
(%) | CI 95% | (%) | CI 95% | (%) | CI 95% | (%) | CI 95% | |
Sensibility | 89 | 84–94 | 94 | 90–98 | 59 | 39–80 | 80 | 66–94 |
Specificity | 99 | 97–100 | 98 | 97–100 | 100 | 100–100 | 100 | 100–100 |
PPV | 96 | 92–99 | 94 | 90–98 | 100 | 100–100 | 100 | 100–100 |
NPV | 96 | 94–98 | 98 | 96–100 | 67 | 49–84 | 92 | 86–98 |
LR+ | 59.91 | 27.0–132.8 | 56.8 | 27.2–118.5 | ||||
LR− | 0.11 | 0.07–0.17 | 0.06 | 0.03–0.12 | 0.41 | 0.25–0.68 | 0.20 | 0.10–0.41 |